What is the reporting period for a DSUR?
Therefore, the first DSUR can be submitted to a concerned MS earlier than 1 year, but the covered reporting period should not be longer than 1 year.
What is Icsr case processing?
The collection and processing of Individual Case Safety Reports (ICSRs) is a fundamental component of the pharmacovigilance system. Systems must be in place to ensure the collection and management of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) from interventional clinical trials.
What are the different types of Icsr?
Types of ICSR reports
- Interventional Clinical Trail/Studies.
- Non-Interventional Clinical Trial/Study.
- Non-Interventional Programmes.
- Patient Registries.
- Patient support & Market research programmes.
- Investigator Initiated clinical Trails, Compassionate use programmes etc.,
When should a DSUR be submitted?
The DSUR should be submitted to all concerned regulatory agencies no later than 60 calendar days after the DSUR data lock point.
What makes a valid Icsr?
A valid ICSR should include at least one identifiable reporter, one single identifiable patient, at least one suspect adverse reaction and at least one suspect medicinal product.
What are the timelines for pharmacovigilance?
In the case of SUSAR (LT/fatal), the regulatory authority has a timeline of 7 calendar days to begin filing ICSR. If SUSAR is not fatal the regulatory authority has 15 calendar days to file an ICSR. A non-serious AE needs to be reported under 90 calendar days.
Is a DSUR the same as Ind annual report?
Generally, the contents of a DSUR and annual report are fairly similar (as outlined above). However, the DSUR tends to be a little more detailed in its data analysis and has a slightly stronger focus on potential impacts on patients.
Is a Susar an Icsr?
The reporting of side effects /ICSRs/ is regulated by the EU announcement of 26/2004 ,EU Regulation No. 2001/83 / EC Directive and EUDRALEX Volume 9A. The procedure applies to adverse events, product problems and customer complaints reporting.
What is expedited reporting in pharmacovigilance?
What Is Expedited Reporting? In the EU post-marketing environment, an Individual Case Safety Report (ICSR) may involve a serious or non-serious adverse reaction – regardless of expectedness. Such cases must be submitted to the regulatory authorities within 15 days or 90 days respectively.
What is R2 and R3 in pharmacovigilance?
This method of assessment should provide evaluation and EU result of the Assessment. The same assessment is used in E2B (R2), with the free text fields, while in E2B (R3) these fields are controlled by origin, method and result of the assessment, according to ISO ICSR.